Vaxcyte, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Vaxcyte completed enrollment of three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) with 6,191 total adults dosed (~3,500 VAX-31); OPUS-1 topline data expected Q4 2026, OPUS-2/OPUS-3 results in H1 2027. Company appointed vaccine industry veterans Dr. Moncef Slaoui (ex-Operation Warp Speed, GSK) and Dr. John Markels (ex-Merck Vaccines President) to board. Cash position: $2.51B as of June 30, 2026. Q2 2026 R&D spending surged 38% YoY to $267.9M; net loss doubled to $284.3M.
Why this rating
Phase 3 enrollment completion is milestone; OPUS-1 noninferiority vs. PCV20/PCV21 is pivotal for BLA path. Board appointments add credible vaccine expertise. However, 38% YoY R&D cost increase and doubled net loss signal substantial cash burn. $2.5B runway is 6-8 quarters at current burn—material but adequate for near-term catalysts.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.